BGLC — BIONEXUS GENE LAB CORP
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| $3.1M | -67.3% | -$2.6M | — | -33.1% | 17.0% | -376.1% | — | — | — | — |
Revenue YoY trend Net margin trend
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 4 SEC-registered investment managers reported holding BGLC (BIONEXUS GENE LAB CORP) in their latest 13F filings, with a combined reported value of $558 across 457 shares. That is +334.3% by share count (+341 shares) versus the previous quarter, while reported value moved +171.4%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 2 added to existing stakes, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of BIONEXUS GENE LAB CORP (BGLC) include HRT FINANCIAL LP, Citadel Advisors, Virtu Financial LLC, ranked by reported 13F value among the 15 institutional holders on this page.
BGLC is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 4 | 457 | $558 | +334.3% |
| Q2 2026 | 3 | 14.38K | $27.20K | -56.3% |
| Q1 2026 | 2 | 232 | $497 | — |
| Q3 2025 | 1 | 7.63K | $41.71K | -20.2% |
| Q2 2025 | 1 | 9.56K | $29.36K | +238950.0% |
| Q1 2025 | 4 | 157.99K | $37.35K | -82.2% |
| Q4 2024 | 6 | 178.10K | $49.82K | +22.8% |
| Q3 2024 | 4 | 130.33K | $58.23K | +0.0% |
Over the 8 quarters shown, institutional share counts decreased 100% in aggregate (Q3 2024 → Q3 2026); the largest single-quarter swing was Q2 2025 (+238950.0%).
Top Institutional Holders (Q3 2026) — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 306 | $373 | 0.00% | Add | |
| 137 | $167 | 0.00% | Add | |
| 12 | $15 | 0.00% | New | |
| 2 | $3 | 0.00% | New |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 14.28K | $27.00K | 0.00% | New | |
| 101 | $197 | 0.00% | Reduce | |
| 1 | $2 | 0.00% | New |
Q1 2026 — 2 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 231 | $495 | 0.00% | New | |
| 1 | $2 | 0.00% | New |
Q3 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 7.63K | $41.71K | 0.00% | Reduce |
Q2 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 9.56K | $29.36K | 0.00% | Add |
Q1 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 98.77K | $23.35K | 0.00% | New | |
| 35.53K | $8.40K | 0.00% | New | |
| 23.68K | $5.60K | 0.00% | Hold | |
| 4 | $1 | 0.00% | Reduce |
New Positions (Q3 2026)
- Tower Research Capital LLC (TRC) 12 sh · $15
- JPMorgan Chase & Co 2 sh · $3
Fully Exited (vs previous quarter)
- HRT FINANCIAL LP sold 14.28K sh · $27.00K
Fund Position History — shares by quarter (top 15 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UBS Group AG | 306 | 101 | 231 | 7.63K | 9.56K | 4 | 109.63K | 83.31K | — | 8.42K | — | — |
| Caitong International Asset Management Co., Ltd | 137 | 1 | — | — | — | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 12 | — | — | — | — | — | — | — | — | — | 5.83K | — |
| JPMorgan Chase & Co | 2 | — | — | — | — | — | 580 | — | — | — | — | — |
| Virtu Financial LLC | — | — | — | — | — | — | — | — | 27.37K | 47.04K | 26.15K | 59.69K |
| Citadel Advisors | — | — | — | — | — | 98.77K | — | — | — | — | 33.59K | 51.75K |
| HRT FINANCIAL LP | — | 14.28K | — | — | — | — | — | — | 14.67K | 21.90K | — | 45.47K |
| TWO SIGMA SECURITIES, LLC | — | — | — | — | — | — | — | — | — | — | 14.92K | 22.99K |
| Geode Capital Management | — | — | — | — | — | 23.68K | 23.68K | 23.68K | 23.68K | 23.68K | 23.68K | 23.68K |
| XTX Topco Ltd | — | — | — | — | — | — | 32.83K | — | — | — | — | — |
| Two Sigma Investments | — | — | — | — | — | 35.53K | — | — | — | — | — | — |
| Cambridge Investment Research Advisors, Inc. | — | — | — | — | — | — | — | 12.96K | — | — | — | — |
| Scientech Research LLC | — | — | — | — | — | — | 10.80K | 10.38K | — | — | — | — |
| Morgan Stanley | — | — | — | — | — | — | 580 | — | — | — | — | — |
| Wells Fargo & Co | — | — | 1 | — | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold BGLC?
As of 2026-Q3, 4 institutional funds reported holding BGLC (BIONEXUS GENE LAB CORP) in SEC 13F filings, with a combined reported value of $558.
How many shares of BGLC do institutions own?
13F filers reported 457 shares of BGLC, worth $558 in aggregate at the end of 2026-Q3.
Is institutional ownership of BGLC rising or falling?
Share counts moved +334.3% versus the prior quarter — accumulation.
Who are the top institutional holders of BGLC?
The largest 13F holders are HRT FINANCIAL LP, Citadel Advisors, Virtu Financial LLC, XTX Topco Ltd, Two Sigma Investments; the top 25 are ranked at the top of this page.
Who are the major shareholders of BIONEXUS GENE LAB CORP?
The major shareholders of BIONEXUS GENE LAB CORP (BGLC) by reported 13F value are HRT FINANCIAL LP, Citadel Advisors, Virtu Financial LLC, XTX Topco Ltd, Two Sigma Investments, among 15 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.